Today, the screeners at HealthTechMovers.com picked up 3 HealthTech Stocks up over 101% past 10 days and have been added to our watchlist. These are very volatile stocks so please do your own research before you make any investments. While we list the ratings of various 3rd party services, we're not recommending these stocks and we're not paid by the featured tickers, we simply report the big movers. If the editor has a position, it will be noted below the charts.
PoliticsAndMyPortfolio.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
Summary: Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.
Recent NVTA Stock Price (approx 10:00am EST.): $5.87
Previous Close for NVTA Stock: $5.37
Percentage Price Change Past 10 Days for NVTA stock: +183%
TipRanks.com reports that Invitae stock currently has 8 analysts offering 12-month price targets and the consensus is a Hold rating for NVTA stock with an average price target is $2.88.
Click here to get the full story on NVTA stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO.
Recent BCAB Stock Price (approx 10:00am EST.): $7.03
Previous Close for BCAB Stock: $6.99
Percentage Price Change Past 10 Days for BCAB stock: +106%
Click here to get the full story on BCAB stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template.
Recent PACB Stock Price (approx 10:00am EST.): $8.83
Previous Close for PACB Stock: $8.79
Percentage Price Change Past 10 Days for PACB stock: +101%
TipRanks.com reports that Pacific Biosciences stock currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating for PACB stock with an average price target is $10.00.
Click here to get the full story on PACB stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Just a reminder, one resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
The other great tool for charting is TradingView.com, so you might want to check that out too.
The information in this article was pulled from third part services. The prices listed above are not real-time and will be delayed at least 15 minutes.
PoliticsAndMyPortfolio.com keeps our subscribers informed of breaking news, reports, stock news or information that can have a positive or negative impact on their portfolio. We look at world events, political activity and the movement of stocks, bonds, metals, commodities and more to provide investors with timely information. Join thousands of investors who already signed up for our free subscription to PoliticsAndMyPortfolio.com.